NCT04172779 2025-11-20
ECHO-B
University of Texas Southwestern Medical Center
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00832637 2018-06-29
Gem-ox
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00532441 2016-02-12
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00365391 2015-07-09
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00033462 2013-06-04
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00047333 2013-01-23
Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00287222 2011-07-15
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
University of Arkansas
Phase 2 Completed